Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-75
SponsorFeixue Song
About this trial
This study explores the effectiveness of combining electroacupuncture with olanzapine-containing four-drug antiemetic therapy to mitigate chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer. The research aims to assess the adjunctive benefits of electroacupuncture in enhancing the antiemetic effects of conventional medication, particularly in the context of highly emetogenic chemotherapy regimens. By investigating the synergistic potential of these modalities, the study seeks to provide insights into optimizing supportive care strategies for patients with breast cancer undergoing intensive chemotherapy treatment.
Eligibility criteria
Qualifiers
Patients aged 18 to 75 years, inclusive, from any nationality.
Patients diagnosed with early-stage breast cancer.
Eastern Cooperative Oncology Group performance status ranging from 0 to 2.
All patients must undergo highly emetogenic chemotherapy (HEC).
Disqualifiers
Scheduled to undergo chemotherapy between days 2 to 4 following HEC.
Received or is planned to receive abdominal radiation therapy within 1 week before Day 1 in cycle 1.
Significant medical or psychological conditions.
Presents with symptomatic primary or metastatic central nervous system malignancy causing nausea and/or vomiting.
Trial design
Treatments tested in this trial
- Electroacupuncture
- Antiemetic Therapy
- Sham electroacupuncture
- Antiemetic Therapy
Treatment groups
370 Participants
are divided into 2 treatment groupsSponsors and collaborators
Feixue Song
Lead sponsor
Lanzhou University Second Hospital
Sponsor institution
Source ClinicalTrials.gov